The forecasted mortality rate for cervix uteri malignant neoplasms in the US is expected to remain constant at 2.6 deaths per hundred thousand women from 2024 to 2028. The value for 2023 stood at 2.6, indicating no variation in the annual rate. Over this period, the year-on-year change shows a 0% variation, and the five-year CAGR indicates a stable trend with an average change of 0%, signifying that no increase or decrease is expected in the mortality rate from this form of cancer.
Future trends to watch for include advancements in screening technology, improved access to healthcare services, and the impact of vaccination programs, which could potentially influence and reduce mortality rates beyond this forecasted stability.
